Drug Profile

Research programme: decoy oligonucleotide therapeutics - AnGes

Alternative Names: NF-kappa-B/E2F decoy oligonucleotide; NF-kappa-B/Ets decoy oligonucleotide

Latest Information Update: 03 Jan 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AnGes MG
Developer AnGes; Osaka University
Class Oligonucleotides
Mechanism of Action E2F transcription factor inhibitors; Matrix metalloproteinase inhibitors; NF-kappa B inhibitors; Proto-oncogene protein c-ets inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

03 Jan 2020 AnGes MG is now called AnGes
16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-disorders in Japan (Parenteral)
30 Nov 2011 Pharmacodynamics data from a preclinical study in Vascular disorders released by AnGes MG

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com